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INTRODUCTION

ABSTRACT
Malingering can be a difficult diagnosis to discern, especially in patients with well-crafted stories presenting with signs
and symptoms that align directly with the literature. This can
further become a challenge when a patient is malingering
in the setting of a rare disease, where many complaints can
be subjective in nature and not entirely testable by physical
exam alone. Malingering is responsible for billions of dollars of
healthcare waste every single year, and this report can serve as
a guide of history elements, signs and symptoms to look out
for with patients malingering in the setting of the porphyrias. It
is important to recognize when patients are malingering, and
when they are not, so that they may receive the appropriate
care to help with their condition. This report can also serve as a
guideline for what laboratory tests and studies to order in the
setting of a suspected porphyria case, in order to confirm the
diagnosis and get the patient the appropriate treatment regimen. Intelligent malingering is a growing problem, especially
with the amount of access the general public has to medical
information, and it is important for us to be able to identify
when a patient is truly suffering from a rare disease and when
they are malingering.

P

orphyria Variegata is a very rare disorder, affecting about 1 in 200,000
of the general population. It is a
genetically inherited metabolic disorder
in which Protoporphyrinogen Oxidase
(PPOX)1, the enzyme that catalyzes the
penultimate step of heme synthesis, is defective leading to the buildup of porphyrin precursors that manifest themselves
as neurological, dermatological and abdominal symptoms. Medically, it is managed with pain control as well as Hemin
infusions which inhibit ALA Synthase1,
the rate-limiting step of heme synthesis
that converts succinyl-CoA and glycine
to aminolevulinic acid, so that toxic heme
precursors do not build up and cause
pain or neuro-visceral symptoms. Acute
attacks can be brought about in times of
stress2, or by use of contraceptives containing progesterone and antibiotics.
Here, we discuss a patient presenting with
an acute porphyria attack determined to
be malingering. We will discuss tactics
for management of patients with extremely intelligent malingering strategies.
CASE PRESENTATION
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34 year old female with a reported PMH
of Porphyria Variegata diagnosed at age 8,
PTSD, anxiety, and right thigh port who
presented with diffuse 9/10 intractable abdominal pain, nausea, vomiting, fatigue,
right sided weakness and claimed photosensitive dermatitis. The patient reported
that 5 days prior she was sexually assaulted
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by her father and was evaluated at an outpatient clinic where she was given antibiotics and contraceptives.
She endorses being unable to return home during that
period to receive her medications including “Dilaudid 2mg for panic attacks”. She endorses developing
nausea, vomiting, abdominal pain, weakness and dermatitis “exactly” similar to previous episodes of acute
porphyria attacks. During the admission process and
encounter, she was given her reported doses of pain
medications. We were unable to independently verify
any medical information for this patient initially, as she
had no forms of identification upon presentation and
could not remember her social security number. We
were unable to obtain hospital records from locations
she had been previously treated, and there was no record of the physician that she claimed had treated her
previously. We were unable to verify her family members that she had reported, as well as the address that
she gave. We were also unable to find any records of
the patient in the PDMP database. As a diagnostic effort, urine testing was ordered to confirm porphobilinogen levels, but the patient refused to give a sample. The
patient also refused to give a urine spot test to confirm
her diagnosis. Hematology questioned whether her
skin lesions accurately reflected photosensitive dermatitis as well. Nursing reported that the patient, when
alone, was resting comfortably, but once surrounded
by providers immediately shifted to a tearful and anxious affect. She would not let physicians examine her,
and was demanding increases in her pain medication,
not allowing pain management to see her. The patient
was finally convinced to give a urine sample, but again
demanded increases in pain medication for intolerable
pain. Seeing as though she was not in acute distress,
the decision was made to switch her medications to
PO rather than IV. Once this decision was made the
patient left AMA. Several days after leaving AMA,
the patient’s urine porphyrins came back as abnormal,
with uroporphyrin 1 being elevated at 21.4, but the other urine porphyrins measured were all within normal
limits. Urine porphobilinogen was 11.5, within normal
limits.
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DISCUSSION AND CONCLUSIONS
The porphyria’s are rare inherited disorders, with subjective complaints that can be taken advantage of in the
setting of malingering. The prevalence of the disease is
estimated at 1 in 200,000 but in groups with South African or Dutch heritage the prevalence is estimated as
1 in 300 likely due to a founder mutation in the PPOX
gene1. Recent studies have shown that in 20% of cases,
both cutaneous lesions and neuro-visceral symptoms
are present, similar to the presentation in our case,
whereas up to 60% of cases present with cutaneous
symptoms only2. The subjective nature of porphyria
symptoms2 make it difficult to distinguish between a
drug seeking patient and a patient that truly needs medical intervention. The major presenting complaints in
our case: GI upset, neurological complaints including
numbness3 and photosensitive dermatitis, are difficult
to confirm in a patient reporting such pain that they do
not want to be examined3 or have lights on them. Our
differential as this patient’s course progressed included
malingering, factitious disorder, somatoform disorder,
and acute porphyria attack. We were able to differentiate between malingering and factitious disorder4 due
to the identifiable source of personal gain (Dilaudid),
whereas in factitious disorders there is the patient has
an uncontrollable desire4 to take on the sick role4, which
this patient did not portray to us. Somatoform disorders
of involuntary nature were also ruled out for this patient due to the patient’s behaviors and symptoms reported4. Our case was complicated by lack of medical
records and a carefully woven story that included all
the details we as physicians look for in a porphyria attack. The workup to confirm an acute attack includes a
urine porphobilinogen spot test and urine porphyrins5.
Patients that refuse to give urine samples over the
course of their time in the ED should raise some minor
suspicion about their situation. Patients requesting exact dosages of narcotic medications should also raise
minor suspicion as well. The story elements that directed us to a porphyria workup6 are the reported history of
porphyria, and the claim that she was given a rape kit
at a clinic. During this patient’s course, some history
elements6 could not be confirmed, at which point it can
be recommended to switch IV medications to PO. Malingering patients may try to extend their hospital stay
by reporting increasing pain, putting physicians in a
tough spot for cases of actual porphyria attacks. In the
case of suspected malingering for narcotics, our goals
should be to completely evaluate all patients so that we
may verify a diagnosis and ensure we deliver the best
medical care possible.
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